SNC-109

N/A

Report date: 2024/01/31 17:13:20

Base Information

Drug NameSNC-109
Drug Alias NameSNC109SNC-109
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionT lymphocyte replacementsAnti-HER2Anti-IL13RA2 +[5] 
TargetsReceptor protein-tyrosine kinase erbB-2Interleukin-13 receptor subunit alpha-2Epidermal growth factor receptor variant III +[4] 
Therapy Area/IndicationsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Simnova Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Simnova Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsGlioblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A